MHLW Panel Recommends Conditional Approval for Nipro’s Stem Cell Product for Spinal Cord Injury

November 26, 2018
A health ministry panel on regenerative medicine products recommended on November 21 conditional, time-limited (seven years) approval for Nipro’s spinal cord injury (SCI) treatment that uses autologous mesenchymal stem cells from bone marrow. The approval is expected before the end...read more